Gene Fusion Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hospitals and Diagnostic Laboratories is the fastest growing sector, North America is the largest market

The Global Gene Fusion Testing Market is projected to expand significantly, from USD 713.68 Million in 2025 to USD 1.45 billion by 2031, demonstrating a robust Compound Annual Growth Rate (CAGR) of 12.66%. Gene fusion testing involves the molecular examination of biological samples to pinpoint hybrid genes resulting from chromosomal rearrangements, which are crucial biomarkers for guiding the selection of targeted tyrosine kinase inhibitor therapies. This market expansion is primarily fueled by the increasing approvals of tissue-agnostic drugs and the rising prevalence of fusion-positive solid tumors, notably non-small cell lung cancer.

The substantial clinical demand for precise genomic identification to inform therapeutic decisions is underscored by projections such as the estimated 226,650 new lung cancer cases in the United States in 2025, highlighting the critical need for these diagnostics. Despite the clear clinical benefits, a significant hurdle for the market remains the inconsistent reimbursement landscape for comprehensive genomic profiling. Variable insurance coverage policies for broad-panel next-generation sequencing often create financial obstacles, limiting patient access to these essential diagnostic tools and thereby impeding their wider commercial adoption across diverse healthcare environments.

Market Drivers

The primary catalyst for the Global Gene Fusion Testing Market is the continuous technological advancement in next-generation sequencing (NGS) and molecular diagnostics, which now enables the simultaneous identification of multiple actionable genomic alterations. Modern NGS platforms have evolved from analyzing single genes to offering comprehensive genomic profiling, significantly boosting the sensitivity required to detect even rare fusion events involving genes such as NTRK, ROS1, and ALK. This technical progress is increasingly validated by regulatory bodies, exemplified by the FDA's January 2025 approval of FoundationOne CDx for identifying BRAF fusions and rearrangements to facilitate targeted pediatric therapies, and is commercially supported by major industry players, with Illumina reporting $1.08 billion in quarterly revenue in Q3 2025, partly driven by accelerated growth in its clinical sequencing segment.

Furthermore, the escalating global incidence of targetable cancer indications significantly propels the demand for precise gene fusion testing. As the burden of oncological diseases worldwide continues to rise, healthcare systems are increasingly prioritizing the identification of specific genomic drivers to enhance treatment efficacy through personalized medicine approaches. The American Cancer Society projected 2,041,910 new cancer cases in the United States in 2025, representing a substantial patient cohort potentially eligible for genomic screening. This growing prevalence necessitates the widespread implementation of fusion-specific diagnostics to accurately guide the administration of tyrosine kinase inhibitors, ensuring gene fusion testing remains an indispensable element within the contemporary oncological care continuum.

Market Challenges

The primary impediment to the commercial expansion of the global gene fusion testing market is the highly variable reimbursement landscape for comprehensive genomic profiling. When payers implement inconsistent coverage policies or deny claims for broad-panel sequencing, clinical laboratories face considerable revenue uncertainty and financial instability. This precarious economic environment actively discourages medical facilities from adopting advanced fusion detection assays, as they cannot guarantee a sufficient return on the significant operational investments associated with next-generation sequencing. Consequently, healthcare providers frequently opt for narrower, more cost-effective testing methods, which directly constrains the overall market volume and hinders the standardization of these crucial diagnostics in routine clinical practice.

Further exacerbating these challenges, federal fee schedule adjustments, such as the estimated 2.5 percent payment reduction for pathology services implemented in 2025 by the College of American Pathologists, intensify the economic pressure on diagnostic providers. This contraction in reimbursement rates severely limits laboratories' capacity to absorb the costs of denied claims and maintain profitability. As facilities struggle to navigate declining payments alongside unpredictable insurance barriers, the accessibility and widespread deployment of gene fusion testing are curtailed, ultimately impeding the sector's financial growth and limiting patient access to advanced precision oncology.

Market Trends

The emergence of liquid biopsy for non-invasive fusion detection represents a transformative shift within the market, effectively overcoming the critical limitation of tissue availability inherent in conventional biopsy procedures. Unlike invasive solid tumor sampling, which can be difficult to repeat, plasma-based next-generation sequencing allows for continuous, longitudinal monitoring of fusion status and the detection of resistance mechanisms through a simple blood draw. This patient-centric method is rapidly gaining widespread traction in clinical settings, enabling providers to bypass significant logistical hurdles associated with tissue acquisition while simultaneously maintaining high diagnostic precision. Florida Cancer Specialists & Research Institute, for instance, reported processing over 16,000 molecular tests by June 2025, a milestone significantly accelerated by the integration of these minimally invasive assay options.

Concurrently, the integration of artificial intelligence (AI) for enhanced bioinformatics analysis is revolutionizing the interpretation of complex genomic data, particularly for accurately identifying rare and cryptic gene fusions. As sequencing panels become more comprehensive, the sheer volume of data generated frequently overwhelms traditional bioinformatic pipelines, potentially leading to false negatives or misinterpretations; AI algorithms effectively mitigate this by distinguishing true fusion events from sequencing artifacts with superior accuracy and efficiency. This technological leap effectively bridges the gap between raw genomic output and actionable clinical insights, exemplified by Gene Solutions Singapore's December 2025 announcement that its proprietary AI-driven platform improved gene fusion detection rates by 20 percent compared to standard analytical methods, thus enhancing diagnostic capabilities.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Amoy Diagnostics Co., Ltd.
• ArcherDX (Integrated DNA Technologies, Inc.)
• Biocartis
• Biocare Medical, LLC
• Guardant Health, Inc.
• Myriad Genetics, Inc.

Report Scope

In this report, the Global Gene Fusion Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Fusion Testing Market, by Category:

• Research
• Diagnostic

Gene Fusion Testing Market, by Technology:

• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)

Gene Fusion Testing Market, by Indication:

• Solid Tumors
• Hematological Malignancies

Gene Fusion Testing Market, by End User:

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Academic & Research Centers

Gene Fusion Testing Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Fusion Testing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.